Search Results

You are looking at 81 - 90 of 449 items for :

  • Refine by Access: All x
Clear All
Full access

Antoine Eskander, Qing Li, Jiayue Yu, Julie Hallet, Natalie G. Coburn, Anna Dare, Kelvin K.W. Chan, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe-Shaw, Monika K. Krzyzanowska, Timothy P. Hanna, Antonio Finelli, Alexander V. Louie, Nicole Look Hong, Jonathan C. Irish, Ian J. Witterick, Alyson Mahar, Christopher W. Noel, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, and Rinku Sutradhar

shade represents the COVID-19 period. When examining incidence trends for each type of cancer separately, the largest immediate drops (by ≥50%) in the volume at the start of the pandemic were seen for melanoma and cervical, endocrine (predominantly

Full access

Nina N. Sanford, David J. Sher, Xiaohan Xu, Chul Ahn, Anthony V. D’Amico, Ayal A. Aizer, and Brandon A. Mahal

drinkers. Of those 84 patients who were currently drinking, 25 (52.1%) exceeded moderate drinking levels and 11 (22.9%) met the criteria for binge drinking (data not shown). Notably, patients with a history of head and neck cancer and/or melanoma, along

Full access

Kelsey C. Stoltzfus, Biyi Shen, Leila Tchelebi, Daniel M. Trifiletti, Niraj J. Gusani, Vonn Walter, Ming Wang, and Nicholas G. Zaorsky

cancer cases are included in the NCDB. 12 We conducted a retrospective analysis of patients diagnosed in 2004 through 2013 with cancer of the following sites: breast, prostate, colon, melanoma, uterus, non–small cell lung, kidney, thyroid, bladder

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Allan R. Oseroff, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, and Linda C. Wang

Full access

Brent E. Pennington and Thomas Stasko

Non-melanoma skin cancers (NMSCs) are the most commonly occurring malignancies in the United States, with over 1 million cases annually. Several subsets of patients within the general population are particularly susceptible to the development of basal cell carcinomas and squamous cell carcinomas. These groups include patients with xeroderma pigmentosum, basal cell nevus syndrome, epidermodysplasia verruciformis, and chronic lymphocytic leukemia as well as organ transplant recipients. Organ transplant recipients are the largest and best characterized of these subsets of patients. Review of the available data regarding the epidemiology, etiology, and clinical features of NMSC in organ transplant patients provides insight into the care of other high-risk patients.

Full access

Vanderbilt-Ingram Cancer Center

Basal cell and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSCS), are the most common skin cancers. More than 1 million cases of NMSC are estimated to be diagnosed each year in the United States and their incidence is rising rapidly. Although rarely metastatic, basal cell and squamous cell cancers can produce substantial local destruction and disfigurement and may involve extensive areas of soft tissue, cartilage, and bone. Updates in the 2007 guidelines include changes to the principles of treatment for both basal cell and squamous cell skin cancers and changes in the consideration of radiotherapy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 0.8 cases per million persons per year. It rarely metastasizes. However, initial misdiagnosis, prolonged time to correct diagnosis, and large tumor size at the time of diagnosis are common. NCCN's Non-Melanoma Skin Cancer panel has developed a guideline outlining treatment of DFSP to supplement the squamous cell and basal cell skin cancers guidelines. The NCCN Sarcoma Panel also provided expert input in the development of this DFSP guideline.

For the most recent version of the guidelines, please visit NCCN.org

Full access

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. A Phase II Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma

Full access

Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St. John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.

Full access

in Subjects With Melanoma With BRAF Non-V600 Mutations Protocol Chair: Douglas B. Johnson, MD, MSCI Institutional Principal Investigators: Michael Davies, MD, PhD; Keith Flaherty, MD; and Tara Gangadhar, MD Conditions: Melanoma